Mikhail Blagosklonny is a professor of Oncology who has a great zeal in ensuring that individuals all over the world live healthily by acquiring the best possible treatment despite their financial and economic status. To achieve this goal Mikhail Blagosklonny has written numerous research articles, book chapters, and reviews. He has also indulged himself in a variety of research which ranges from cellular and molecular biology to clinical investigations with the aim of ensuring that people acquire the best treatments concerning cancer therapies. In his study, Mikhail Blagosklonny has specialized in investigating cancer among the aged people. As a mentor to many, Mikhail Blagosklonny has inspired many of his mentees to continue to expand his research in future to achieve his goal.
Due to his commendable zeal in medical research, Mikhail Blagosklonny has been appointed to many positions. Some of those posts include but not limited to; a professor of medicine at New York Medical College, Senior Scientist at the Ordway Research Institute in New York, a member of journal’s editorial board of Cell Death and Differentiation. In addition to these positions, Mikhail Blagosklonny is an associate editor of Cancer Biology and Therapy in Cell Death and Differentiation editorial board as well as being the founder and editor in chief of Cell Cycle Journal. Through these positions, he has gained numerous skills and experience which has enabled him to contribute a lot in Oncology.
Among some of the articles that he has authored are Aging Hyperfunction theory, Cell Cyclotherapy and Chemotherapeutic Engineering and many others. Through these academic papers, Mikhail Blagosklonny has expressed his certainty that it is possible to prevent cancer and aging. In his hypothesis, he has shown the role of TOR signaling in cancer and aging and still he has suggested Rapamycin as a drug which can increase the lifespan of individuals through its ability to treat cancer and other diseases. The drug has also demonstrated the ability to boost immunity in human hence reducing death rate as well as reducing rejection of organs during an organ transplant. He has also shown that the drug can get administered in the treatment of Alzheimer’s disease through an experiment that involved mice. In that analysis, the medicine revealed its capacity to reduce brain lesion and prevention of cognitive defects in mice. Also, Mikhail Blagosklonny is still carrying out research that aims at knowing whether the drug can get utilized in the treatment of Muscular Dystrophy and Systemic Lupus Erythematosus. He also said aging does not occur as a result of molecular damage but as a result of age-related diseases which can cause death hence reducing human lifespan. Mikhail Blagosklonny has contributed significantly in the field of medicine and more specifically in the prevention of cancer and aging. His hope remains that through his contributions he will inspire many people in the world to continue with his research to achieve his goal of ensuring people will get the best treatments in the world. He also aspires to bring down the costs of such treatments to levels where every person can afford.